Trials / Terminated
TerminatedNCT03793712
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-flexible-dose Study of Lu AF11167 for the Treatment of Persistent Prominent Negative Symptoms in Patients With Schizophrenia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 168 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the efficacy of 2 fixed-flexible doses of Lu AF11167 on negative symptoms in patients with schizophrenia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lu AF11167 (1-2 mg/day) | Fixed-flexible oral dose, tablets. Once daily. 12 weeks. |
| DRUG | Lu AF11167 (3-4 mg/day) | Fixed-flexible oral dose, tablets. Once daily. 12 weeks. |
| DRUG | Placebo | Placebo oral dose, tablets. Once daily. 12 weeks. |
Timeline
- Start date
- 2018-12-27
- Primary completion
- 2020-08-20
- Completion
- 2020-09-03
- First posted
- 2019-01-04
- Last updated
- 2020-09-23
Locations
53 sites across 8 countries: Bulgaria, Czechia, Estonia, Germany, Hungary, Latvia, Poland, Ukraine
Source: ClinicalTrials.gov record NCT03793712. Inclusion in this directory is not an endorsement.